Adaptimmune Therapeutics PLC Annual Income Tax Expense (Benefit) in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2014 to 2023.
  • Adaptimmune Therapeutics PLC Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $526K, a 22.6% decline year-over-year.
  • Adaptimmune Therapeutics PLC Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $1.08M, a 59.9% decline year-over-year.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2023 was $1.34M, a 46.5% decline from 2022.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2022 was $2.5M, a 216% increase from 2021.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2021 was $791K, a 388% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $1.34M -$1.16M -46.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-06
2022 $2.5M +$1.71M +216% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-06
2021 $791K +$629K +388% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-06
2020 $162K -$80K -33.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-06
2019 $242K -$255K -51.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-14
2018 $497K +$46K +10.2% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $451K -$441K -49.4% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-27
2016 $892K +$648K +266% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 $244K +$169K +225% Jul 1, 2014 Jun 30, 2015 10-K 2018-03-15
2014 $75K Jul 1, 2013 Jun 30, 2014 10-K 2017-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.